These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1472041)

  • 1. Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS.
    Veljkovic V; Metlas R; Raspopovic J; Pongor S
    Biochem Biophys Res Commun; 1992 Dec; 189(2):705-10. PubMed ID: 1472041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120.
    Veliković V; Metlas R; Danilo V; Cavor L; Pejinović N; Dujuć A; Zakhariev S; Guarnaccia C; Pongor S
    Biochem Biophys Res Commun; 1993 Nov; 196(3):1019-24. PubMed ID: 8250861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease.
    Veljkovic N; Branch DR; Metlas R; Prljic J; Vlahovicek K; Pongor S; Veljkovic V
    J Pept Res; 2003 Oct; 62(4):158-66. PubMed ID: 12969195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease.
    Veljkovic V; Metlas R
    Int Rev Immunol; 2004; 23(5-6):437-45. PubMed ID: 15370275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1.
    Yang X; Tomov V; Kurteva S; Wang L; Ren X; Gorny MK; Zolla-Pazner S; Sodroski J
    J Virol; 2004 Dec; 78(23):12975-86. PubMed ID: 15542649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perturbation of in vitro HIV pathogenic effects by peptides showing sequence similarities with the C2 conserved domain of gp120.
    Lafont V; Nicolas M; Dornand J; Liautard JP; Favero J
    Immunol Lett; 1993 Aug; 37(2-3):249-50. PubMed ID: 8258463
    [No Abstract]   [Full Text] [Related]  

  • 7. Natural autoantibodies in healthy neonatals recognizing a peptide derived from the second conserved region of HIV-1 gp120.
    Vujicić AD; Gemović B; Veljković V; Glisić S; Veljković N
    Vojnosanit Pregl; 2014 Apr; 71(4):352-61. PubMed ID: 24783415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuity and discontinuity in the anti-V3 IgG response of human immunodeficiency virus type 1-infected persons in a cross-sectional and longitudinal study using synthetic peptides.
    Lawoko A; Johansson B; Dash R; Falck L; Dietrich U; Pipkorn R; Nilehn B; Blomberg J
    J Infect Dis; 1995 Sep; 172(3):682-90. PubMed ID: 7658059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis.
    Zagury JF; Bernard J; Achour A; Astgen A; Lachgar A; Fall L; Carelli C; Issing W; Mbika JP; Picard O
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7573-7. PubMed ID: 8356059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins.
    Hötzel I; Cheevers WP
    J Virol; 2001 Feb; 75(4):2014-8. PubMed ID: 11160703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients.
    Ghetie V; Slaughter C; Wheeler HT; Uhr JW; Vitetta ES
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5690-3. PubMed ID: 2062847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversity of HIV type 1 envelope V3 loop region in saliva.
    Kakizawa J; Ushijima H; Morishita Y; Oka S; Ikeda Y; Müller WE
    AIDS Res Hum Retroviruses; 1996 Apr; 12(6):561-3. PubMed ID: 8679313
    [No Abstract]   [Full Text] [Related]  

  • 15. Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistance to disease development.
    Neurath AR; Strick N; Taylor P; Rubinstein P; Stevens CE
    AIDS Res Hum Retroviruses; 1990 Oct; 6(10):1183-92. PubMed ID: 1701315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?
    Veljkovic M; Branch DR; Dopsaj V; Veljkovic V; Veljkovic N; Glisic S; Colombatti A
    Med Hypotheses; 2011 Sep; 77(3):404-8. PubMed ID: 21684085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand.
    McCutchan FE; Viputtigul K; de Souza MS; Carr JK; Markowitz LE; Buapunth P; McNeil JG; Robb ML; Nitayaphan S; Birx DL; Brown AE
    AIDS Res Hum Retroviruses; 2000 May; 16(8):801-5. PubMed ID: 10826486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.